medigraphic.com

2014, Number 1

<< Back Next >>

Cir Cir 2014; 82 (1)

Medullary carcinoma experience in breast oncology unit of Hospital Juarez Mexico

Jiménez-Villanueva X, Hernández-Rubio Á, García-Rodríguez FM, Gil-García R, Moreno-Eutimio M, Herrera-Torres A

Language: Spanish
References: 22
Page: 20-27
PDF size: 557.01 Kb.


ABSTRACT

Background: Medullary breast cancer is a rare type, considered of good prognosis.
Objective: To know the epidemiological and clinical characteristics of the population attended in the Hospital Juarez de Mexico, to know if they are alike to described worldwide and if the treatments proposed internationally are applicable for this hospitable center.
Methods: We performed a retrospective analysis. Reviewing the records with histopathologic diagnosis of medullary breast cancer from February 1993 to February 2011. Finding 41 patients in the oncology unit of the institution.
Results: We report an incidence of 3.04%, originating in 11 Mexican States, with a low to middle socioeconomic level in 39.02%. The average age at the time of diagnosis was 50 years. No family history was reported but some patients had medical history for type 2 diabetes, hypertension and previous breast cancer. 63.41% were menopausal. The average clinical size of the tumor was 58 mm. The 63% of the cases were located in the left breast. The 53.1% were clinical stages I and II, 46.3% were clinical stages III and in 9.6% of the cases primary tumor could not be assessed. Only 47% of the patients had positive axillary lynph nodes at diagnosis. The inmunohistochemestry was only reported in 14 of the 41 patients, according to the molecular classification of breast cancer: 8 were triple negative, 2 luminal A, 1 luminal B and 3 Her2neu.
Conclusions: The Mexican population presents epidemiological and clinical characteristics similar to those patients described in other studies worldwide.


REFERENCES

  1. Flores L, Arlen M, Elguezabal A, Livingston SF, Levowitz BS. Host tumor relationships in medullary carcinoma of the breast. Surg Gynecol Obstet 1974;139:683-688.

  2. Schwartz GF. Solid circumscribed carcinoma of the breast. Ann Sug 1969;169:165-173.

  3. Geschickter CF. Diseases of the breast: Diagnosis, Pathology, Treatment. 2nd ed. Philadelphia: JB Lippincott, 1945;565- 575.

  4. Bloom HJG, Richardson WW, Fields JR. Host resistance and survival in carcinoma of breasts. A study of 104 cases of medullary carcinoma in a series of 1411 cases of breast cancer followed 20 years. Br Med J 1970;3:181-188.

  5. Wilson AF, Bailey-Wilson JE, Cleton FJ, Elston RC, King MC, Linkage analysis of Dutch families at high risk for breast cancer. Genet Epidemiol 1986;3(suppl 1):87-92.

  6. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002;34:309-314.

  7. Shousha S. Medullary carcinoma of the breast and BRCA1 mutation. Histopatology 2000;37:182-185.

  8. Ben-Ezra J, Sheibani K. Antigenic phenotype of the lymphocytic component of medullary carcinoma o the breast. Cancer 1987;59:2037-2041.

  9. Harris M, Lessells AM. The ultrastructure of medullary, atypical medullary and non-medullary carcinomas of the breast. Histopathology 1986;10:405-414.

  10. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Eiormetrika 1965;52:203- 223.

  11. Jensen ML, Kiaer H, Andersen J, Jensen V, Melsen F. Prognostic Comparison of three classifications for medullary carcinomas of the breast. Hystopathology 1997;30:523- 532.

  12. Moore OS, Foote FW. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949;2:635-642.

  13. Richardson WW. Medullary Carcinoma of the Breast. A Distinctive Tumor Type with a Relatively Good Prognosis following Radical Mastectomy. Br J Cancer 1956;10:415-423.

  14. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC, et al. The pathology of invasive breast cancer A Syllabus Derived from Findings of the National Surgical Adyuvant Breast Project (Protocol No. 4). Cancer 1975;36:1-85.

  15. Crotty TB. Medullary carcinoma: it is a reproducible and pronostically significant type of mammary carcinoma? Adv Anat Pathol 1996;3:179-184.

  16. Gaffey MJ, Mills SE, Frierson HF Jr., Zarbo RJ, Boyd JC, Simpson JF, et al. Medullary carcinoma of the breast: Interobserver variability in histopatologic diagnosis. Mod Pathol 1995;8:31-38.

  17. Macmahon B, Morrison AS, Ackerman LV, Lattes R, Taylor HB, Yuasa S. Histologic characteristics of breast cancer in Boston and Tokyo. Int J Cancer 1973;11:338-344.

  18. Rosen PP, Ashikari R, Thaler H, Ishikawa S, Hirota T, Abe O, et al. A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA. Cancer. 1977;39:429-434.

  19. Wynder EL, Kajitani T, Kuno J, Lucas JC, DePalo A, Farrow J. A comparison of survival rates between American and Japanese patients with breast cancer. Surg Gynecol Obstet. 1963;117:196-200.

  20. Foote FW. Surgical Pathology of Cancer of the Breast. In: Parsons WH ed. Cancer of the Breast. Springfield III, CC. Thomas, 1959;38-40.

  21. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast. A clinicopathologic study with 10 years follow up. Cancer 1977;40:1365-1385.

  22. Rosai J. Rosai and Ackerman´s Surgical Pathology. 10th ed. China: Elsevier, 2011;1670-1671.




2020     |     www.medigraphic.com